Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer

Kayahan N., Karaca M., SATIŞ H., YAPAR D., ÖZET A.

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.51, no.4, pp.1727-1732, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 51 Issue: 4
  • Publication Date: 2021
  • Doi Number: 10.3906/sag-2009-115
  • Journal Name: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.1727-1732
  • Keywords: Pancreatic cancer, folfirinox, gemcitabine-cisplatin, effectiveness, side effect, RANDOMIZED PHASE-III, PLUS CISPLATIN, TRIAL, OXALIPLATIN, CARCINOMA, EFFICACY
  • Gazi University Affiliated: Yes

Abstract

Background/aim: The purpose of this study was to compare efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine-cisplatin as first-line therapy in patients with pancreatic cancer. Materials and methods: Pancreaticobiliary cancer patients who had Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating greater severity of illness) were evaluated to receive folfirinox or gemcitabine plus cisplatin. The primary endpoints were progression-free and overall survival time. Safety analysis was also evaluated as secondary measures. Results: There were 32 patients in the folfirinox group and 36 patients in the gemcitabine-cisplatin group. The median overall survival was 18.1 months (7.5-28.7) in the folfirinox group as compared with 9.7 months (6.5-13) in the gemcitabine-cisplatin group (p = 0.009). Median progression-free survival was 16.2 months (9-23.4) in the folfirinox group and 6.9 months (6.1-7.6) in the gemcitabinecisplatin group (p = 0.001). Conclusion: Folfirinox is an option for the first-line treatment of patients with pancreatic cancer and good performance status.